If management are working in the interest of shareholders, I wonder what the next move would be. Progress with EMA approved phase III trial or continue trying to harmonise studies leading to delay of progress and likely reduction of SP.
The shorter term part of me hopes progress with EMA trial and stop the share price bleeding and continue discussions with FDA in parallel. Partner with big pharma with EMA progress/results then head to the FDA with a big tailwind. An answer by mid July I would expect.
If management are working in the interest of shareholders, I...
-
- There are more pages in this discussion • 133 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IXC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $5.335M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 532 | 7.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.5¢ | 8695 | 1 |
View Market Depth
| Last trade - 10.04am 09/08/2024 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable